E
NAGE

Ergoteles’s Niagen Bioscience NAGE Stock Holding History

Ergoteles’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-26,170
Closed -$44K – 1837
2022
Q4 		$44K Sell
26,170
-101,041
-79% -$160K ﹤0.01% 1308
2022
Q3 		$156K Sell
127,211
-103,089
-45% -$166K 0.01% 1267
2022
Q2 		$385K Buy
+230,300
New +$450K 0.01% 975
2021
Q3 		– Sell
-13,400
Closed -$132K – 1761
2021
Q2 		$132K Buy
+13,400
New +$117K ﹤0.01% 1360

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Ergoteles's NAGE Position: Q1 2023 in Review

Ergoteles sold out of Niagen Bioscience (NAGE) in Q1 2023, closing a stake of 26,170 shares — an estimated $44K sold.

Ergoteles first reported a position in NAGE in Q2 2021 and held it in 4 quarters. The position peaked at $385K in Q2 2022. 59 funds tracked by Wall St. Rank hold NAGE as of Q1 2023.

  • Ergoteles reported no remaining Niagen Bioscience position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 26,170 Niagen Bioscience shares in Q1 2023, an estimated $44K.
  • Ergoteles first reported a position in Niagen Bioscience in Q2 2021 and held it in 4 quarters.
  • Ergoteles's Niagen Bioscience position peaked at $385K in Q2 2022.
  • 59 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.